• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
ConclusionThe diagnosis of IMNM does not always take into account recent criteria for the diagnosis of this pathology. This study highlights the existence of a signal, as well as the need for collaboration between oncologists and neurologists for these neurological pathologies.
Source: European Journal of Clinical Pharmacology - March 17, 2022 Category: Drugs & Pharmacology Source Type: research

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non ‐small cell lung cancer: Management of adverse events
ConclusionsThe adherence to lung dose constraints such as V20 as well as close treatment monitoring are a prerequisite for the management of pneumonitis during maintenance therapy with durvalumab.
Source: Thoracic Cancer - March 16, 2020 Category: Cancer & Oncology Authors: Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, Takanori Abe, Shin ‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu Tags: ORIGINAL ARTICLE Source Type: research

Myasthenia gravis and myopathy after nivolumab treatment for non ‐small cell lung carcinoma: A case report
Here, we report a case of myasthenia gravis and myopathy in a patient treated with nivolumab. A 76 ‐year‐old man who had been treated with four doses of nivolumab because of non‐small cell lung cancer (NSCLC) presented with proximal‐dominant muscle weakness and fluctuating ptosis and diplopia. Serologic studies revealed increased levels of muscle enzymes including creatine phosphokinase ( 2934 U/L), and acetylcholine receptor antibody was positive (1.31 nmol/L). Following electrodiagnostic study, he was diagnosed with myasthenia gravis and active stage of myopathy. After discontinuation of nivolumab, he was treated...
Source: Thoracic Cancer - August 20, 2019 Category: Cancer & Oncology Authors: Je ‐Seong Kim, Tai‐Seung Nam, Jieun Kim, Bo‐Gun Kho, Cheol‐Kyu Park, In‐Jae Oh, Young‐Chul Kim Tags: CASE REPORT Source Type: research

7th drug hypersensitivity meeting: part one
Table of contentsOral AbstractsO1 Functionally distinct HMGB1 isoforms correlate with physiological processes in drug-induced SJS/TENDaniel F. Carr, Wen-Hung Chung, Rosalind E. Jenkiins, Mas Chaponda, Gospel Nwikue, Elena M. Cornejo Castro, Daniel J. Antoine, Munir PirmohamedO2 Hypersensitivity reactions to beta-lactams, does the t cell recognition pattern influence the clinical picture?Natascha Wuillemin, Dolores Dina, Klara K. Eriksson, Daniel YerlyO3 Specific binding characteristics of HLA alleles associated with nevirapine hypersensitivityRebecca Pavlos, Elizabeth Mckinnin, David Ostrov, Bjoern Peters, Soren Buus, Davi...
Source: Clinical and Translational Allergy - August 24, 2016 Category: Allergy & Immunology Source Type: research